Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1789636

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1789636

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

PUBLISHED:
PAGES: 247 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

Cell And Gene Therapy Market is estimated to be valued at USD 37.7 Bn in 2025 and is expected to reach USD 125.5 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 37.7 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 18.50% 2032 Value Projection: USD 125.5 Bn

Cell therapy is the introduction of new cells into a patient's body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient's own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can

  • Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
  • To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
  • Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study

  • This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (USD Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cell and gene therapy market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market.

Market Segmentation

  • Global Cell and Gene Therapy Market, By Therapy Type
    • Cell Therapy
    • Stem Cells
    • T Cells
    • Dendritic Cells
    • NK Cells
    • Gene Therapy
    • Germline Gene Therapy
    • Somatic Gene Therapy
  • Global Cell and Gene Therapy Market, By Application
    • Dermatology
    • Musculoskeletal
    • Oncology
    • Immunology
    • Cardiology & Neurology
    • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
  • Global Cell and Gene Therapy Market, By End user
    • Hospitals
    • Clinics
    • Others (Research Institutes, Academic Institutes, etc.)
  • Global Cell and Gene Therapy Market, By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Bluebird Bio, Inc. (Celgene Corporation)
    • Biogen Inc.
    • uniQure N.V.
    • JCR Pharmaceuticals Co. Ltd.
    • Gene Biotherapeutics
    • Kolon TissueGene, Inc.
    • Horama S.A.
    • MeiraGTx Limited
    • Gilead Sciences, Inc.
    • Organogenesis, Inc.
    • Orchard Therapeutics Plc.
    • Freeline Therapeutics Ltd.
    • Bristol-Myers Squibb Company
    • PTC Therapeutics, Inc.
    • Spark Therapeutics, Inc.
    • Biomarin Pharmaceutical Inc.
Product Code: CMI2475

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapy Type
    • Market Snapshot, By Application
    • Market Snapshot, By End user
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Technological Advancements
  • Manufacturer Revenue
  • Pipeline Analysis

4. Global Cell and Gene Therapy Market, By Therapy Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
      • Germline Gene Therapy
      • Somatic Gene Therapy

5. Global Cell and Gene Therapy Market, By Application, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Dermatology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Musculoskeletal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Cardiology & Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends
  • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Segment Trends

6. Global Cell and Gene Therapy Market, By End user, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020-2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Research Institutes, Academic Institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cell and Gene Therapy Market, By Region, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Novartis International AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Regeneron Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bluebird Bio, Inc. (Celgene Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • JCR Pharmaceuticals Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gene Biotherapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kolon TissueGene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Horama S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • MeiraGTx Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Organogenesis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Orchard Therapeutics Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Freeline Therapeutics Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PTC Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biomarin Pharmaceutical Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!